Ganga Pharmaceuticals Ltd (GANGAPHARM)

Loading page…

Ganga Pharmaceuticals Ltd (GANGAPHARM) · mywealthgrid

About

Ganga Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹7 Cr

P/E

73.8×

P/B

—

Dividend yield

ROE

—

ROCE

—

Debt / equity

—

OPM

1.4%

EPS (TTM)

₹0.2

Book value

—

52-week high

—

52-week low

—

208 historical price candles were omitted because the exchange source has not been verified.

Only one verified price point is available. The trend chart will appear when more exchange closes are stored.

Quick read

rule-based

Pros

+Profit CAGR of 38% over the last 5 years

Cons

−Low return on equity of 0.9% (3-yr avg)
−Thin operating margin of 1.4%
−Modest revenue growth of 3.6% a year over the last 5 years
−Expensive at 73.8× trailing earnings
−Promoter holding fell 5.1 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

21/100

Business quality: 4
Growth: 56
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	2	3	3	3	3
COGS	1	1	1	—	—	1
Gross profit	1	1	1	—	—	2
	1	1	1	3	3	1
Operating profit (EBITDA)	0	0	0	0	-0	0
OPM %	0.8%	1.2%	0.4%	2.2%	-4.2%	1.4%
Depreciation	0	0	0	0	0	0
Interest	0	0	0	0	0	0
	0	0	0	0	0	0
Profit before tax	0	0	0	0	0	0
Tax	0	0	0	0	0	0
Tax %	50%	20%	20%	33.3%	0%	23.1%
	0	0	0	0	0	0
PAT margin %	0.8%	1.6%	1.5%	1.8%	3%	3.5%
EPS (₹)	0.1	0.1	0.1	0.1	0.2	0.2
EPS adjusted (₹)	—	0.1	0.1	0.1	0.2	—
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	—	4	4	5	5	—
Reserves	—	1	1	2	2	—
	—	2	2	1	1	—
	8	1	1	1	1	10
Total equity & liabilities	8	8	8	9	9	10
	—	1	1	1	1	1
CWIP	—	—	—	—	—	—
Investments	0	0	0	0	0	0
	8	7	7	8	8	9
Total assets	8	8	8	9	9	10

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	-0	-0	-1	-1	-1
	0	0	0	0	1	0
	-0	0	-0	1	-0	1
Net cash flow	0	0	0	0	0	-0
Free cash flow	-0	-0	-0	-1	-1	-1
CFO / Operating profit %	-900%	-700%	-400%	—	—	—

Compounded sales growth

7 years: —
5 years: 4%
3 years: 3%
1 year: 7%

Compounded profit growth

7 years: —
5 years: 38%
3 years: 36%
1 year: 25%

Return on equity

7 years: —
5 years: —
3 years: 1%
Last year: 1%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	47.7%	49%	52.1%	—	—	54.1%
EBITDA margin %	0.8%	1.2%	0.4%	2.2%	-4.2%	1.4%
EBIT margin %	-1.3%	-0.8%	-1.9%	0.4%	-6.1%	-0.7%
PAT margin %	0.8%	1.6%	1.5%	1.8%	3%	3.5%
Working capital
Receivable days	—	130	125	123	126	—
Inventory days	333	331	347	169	157	328
Payable days	—	—	—	—	—	—
NWC days	—	—	—	—	—	—
Leverage
Current ratio	2.85	2.91	2.72	4.79	4.29	6.1
Debt to EBITDA	—	64.33	182	22.5	—	—
Debt to equity	—	0.36	0.33	0.21	0.22	—
Interest coverage	1.2	1.3	1.3	1.4	1.6	2
Asset turnover	0.31	0.31	0.32	0.32	0.29	0.29
Return ratios
Return on assets %	0.3%	0.5%	0.5%	0.6%	0.9%	1%
Return on capital employed %	3.6%	3.9%	4%	3.7%	3.8%	3.3%
Return on equity %	—	0.7%	0.7%	0.8%	1.2%	—

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
	56.02%	56.02%	50.91%	50.91%	50.91%
FII	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%
	43.98%	43.98%	49.09%	49.09%	49.09%
No. of shareholders	365	368	367	366	365

Promoter holding down 5.11 percentage points since Sep 2024.

Mr. Sanjay V. KulkarniChiarman - Non-Executive Director
Mr. Bharat Brijmohan SharmaManaging Director
Anagh B SharmaChief Financial Officer
Mrs. Srijna Bharat SharmaWhole-Time Director
Mr. Aman Mukesh ChaudhariNon - Executive Independent Director
Mr. Munna Baijnath ChaurasiaNon - Executive Independent Director
Ms. Priti BhaiyaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Ganga Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

5 announcementsExport CSV

2 Sept 2026, 7:33 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	47.7%	49%	52.1%	—	—	54.1%
EBITDA margin %	0.8%	1.2%	0.4%	2.2%	-4.2%	1.4%
EBIT margin %	-1.3%	-0.8%	-1.9%	0.4%	-6.1%	-0.7%
PAT margin %	0.8%	1.6%	1.5%	1.8%	3%	3.5%
Working capital
Receivable days	—	130	125	123	126	—
Inventory days	333	331	347	169	157	328
Payable days	—	—	—	—	—	—
NWC days	—	—	—	—	—	—
Leverage
Current ratio	2.85	2.91	2.72	4.79	4.29	6.1
Debt to EBITDA	—	64.33	182	22.5	—	—
Debt to equity	—	0.36	0.33	0.21	0.22	—
Interest coverage	1.2	1.3	1.3	1.4	1.6	2
Asset turnover	0.31	0.31	0.32	0.32	0.29	0.29
Return ratios
Return on assets %	0.3%	0.5%	0.5%	0.6%	0.9%	1%
Return on capital employed %	3.6%	3.9%	4%	3.7%	3.8%	3.3%
Return on equity %	—	0.7%	0.7%	0.8%	1.2%	—

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
2 Sept 2026, 7:33 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
1 Sept 2026, 7:56 pm	Company Update General	The Company Has Sent Letter To The Shareholder For AGM Whose Email Id Is Not Registered With RTA.	PDF
1 Sept 2026, 7:40 pm	AGM/EGM AGM	Notice Of The AGM For F.Y. 2025-26	PDF
1 Sept 2026, 7:37 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
1 Sept 2026, 7:29 pm	AGM/EGM AGM	Intimation For 37Th Annual General Meeting Scheduled To Be Held On Saturday, September 26, 2026	PDF

Ganga Pharmaceuticals Ltd